Overview

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HE

Status:
Unknown status

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+). A new high potential trastuzumab conjugate T-DM1(trastuzumab was linked with the cytotoxic agent mertansine DM1)was tested with endocrine therapy and without against a standard arm with trastuzumab and endocrine therapy.

Phase:

Phase 2

Details

Lead Sponsor:

West German Study Group

Collaborator:

Roche Pharma AG

Treatments:

Ado-trastuzumab emtansine
Aromatase Inhibitors
Maytansine
Trastuzumab